Sijie Wang

Nanjing University of Finance and Economics — China

Medicine · Health Sciences

13h-index662citations64works3.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Peptidase Inhibition and Analysis(22), Cholangiocarcinoma and Gallbladder Cancer Studies(20), CAR-T cell therapy research(15), Immunotherapy and Immune Responses(10), Glycosylation and Glycoproteins Research(9)

Publications64 total

Supplementary Table 2 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma
2025Open Access
Supplementary Figures from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma
2025Open Access
Supplementary Table S3 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma
2025Open Access
Supplementary Table S1 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma
2025Open Access
A report for the fifth International Workshop on Rotavirus and Norovirus in China
Human Vaccines & Immunotherapeutics·2025Open Access
Identification of covalent inhibitors of Staphylococcus aureus serine hydrolases important for virulence and biofilm formation
Nature Communications·2025· 3 citedOpen Access
HOUSING PRICE RESTRICTION AND OVERCAPACITY: EVIDENCE FROM CHINA’S PROPERTY TAX PILOT POLICY
The Singapore Economic Review·2025
CDK5-triggered G6PD phosphorylation at threonine 91 facilitating redox homeostasis reveals a vulnerability in breast cancer
Acta Pharmaceutica Sinica B·2024· 6 citedOpen Access
Mechanisms and therapeutic targets of mitochondria in the progression of metabolic dysfunction-associated steatotic liver disease
Annals of Hepatology·2024· 14 citedOpen Access
Covalent-fragment screening identifies selective inhibitors of multiple Staphylococcus aureus serine hydrolases important for growth and biofilm formation
2024Open Access
iTRAQ-based Proteomic Analysis Unveils NCAM1 as a Novel Regulator in Doxorubicin-induced Cardiotoxicity and DT-010-exerted Cardioprotection
Current Pharmaceutical Analysis·2024· 26 cited
Supplementary Table 2 from Targeting CD44 variant 5 with an antibody-drug conjugate is an effective therapeutic strategy for intrahepatic cholangiocarcinoma
2024Open Access
Supplementary Figures from Targeting CD44 variant 5 with an antibody-drug conjugate is an effective therapeutic strategy for intrahepatic cholangiocarcinoma
2024Open Access
Supplementary Table 2 from Targeting CD44 variant 5 with an antibody-drug conjugate is an effective therapeutic strategy for intrahepatic cholangiocarcinoma
2024Open Access
Supplementary Table S3 from Targeting CD44 variant 5 with an antibody-drug conjugate is an effective therapeutic strategy for intrahepatic cholangiocarcinoma
2024Open Access
Supplementary Table S1 from Targeting CD44 variant 5 with an antibody-drug conjugate is an effective therapeutic strategy for intrahepatic cholangiocarcinoma
2024Open Access
Supplementary Table S3 from Targeting CD44 variant 5 with an antibody-drug conjugate is an effective therapeutic strategy for intrahepatic cholangiocarcinoma
2024Open Access
Data from Targeting CD44 variant 5 with an antibody-drug conjugate is an effective therapeutic strategy for intrahepatic cholangiocarcinoma
2024Open Access
Supplementary Table S1 from Targeting CD44 variant 5 with an antibody-drug conjugate is an effective therapeutic strategy for intrahepatic cholangiocarcinoma
2024Open Access
Supplementary Figures from Targeting CD44 variant 5 with an antibody-drug conjugate is an effective therapeutic strategy for intrahepatic cholangiocarcinoma
2024Open Access
page 1 of 4Next →

Frequent Co-authors

Yuncheng Bei(20), Pingping Shen(20), Jian He(18), Yuxin Wang(18), Xuhui Dong(17), Wan Guo(17), Chengjie Cai(17), Zhiye Xu(17), Jia Wei(17), Nan Zhang(17), Baorui Liu(15), Si Li(11), Natnaree Siriwon(11), Xiaoyang Zhang(11), Kwang Gi Kim(11), John Mac(11), Zhengfei Lu(11), Xiaolu Han(11), Pin Wang(11), Feng He(10)